CStone Pharmaceuticals

SEHK:2616 Stock Report

Market Cap: HK$1.9b

CStone Pharmaceuticals Future Growth

Future criteria checks 5/6

CStone Pharmaceuticals is forecast to grow earnings and revenue by 69.5% and 28.5% per annum respectively while EPS is expected to grow by 69.9% per annum.

Key information

69.5%

Earnings growth rate

69.9%

EPS growth rate

Biotechs earnings growth39.3%
Revenue growth rate28.5%
Future return on equityn/a
Analyst coverage

Low

Last updated26 Aug 2024

Recent future growth updates

Recent updates

Improved Revenues Required Before CStone Pharmaceuticals (HKG:2616) Stock's 27% Jump Looks Justified

May 12
Improved Revenues Required Before CStone Pharmaceuticals (HKG:2616) Stock's 27% Jump Looks Justified

Lacklustre Performance Is Driving CStone Pharmaceuticals' (HKG:2616) 28% Price Drop

Mar 04
Lacklustre Performance Is Driving CStone Pharmaceuticals' (HKG:2616) 28% Price Drop

Benign Growth For CStone Pharmaceuticals (HKG:2616) Underpins Stock's 25% Plummet

Jan 18
Benign Growth For CStone Pharmaceuticals (HKG:2616) Underpins Stock's 25% Plummet

The Market Doesn't Like What It Sees From CStone Pharmaceuticals' (HKG:2616) Revenues Yet As Shares Tumble 26%

Oct 04
The Market Doesn't Like What It Sees From CStone Pharmaceuticals' (HKG:2616) Revenues Yet As Shares Tumble 26%

Is CStone Pharmaceuticals (HKG:2616) A Risky Investment?

Oct 03
Is CStone Pharmaceuticals (HKG:2616) A Risky Investment?

Is CStone Pharmaceuticals (HKG:2616) A Risky Investment?

Oct 20
Is CStone Pharmaceuticals (HKG:2616) A Risky Investment?

Is CStone Pharmaceuticals (HKG:2616) Using Too Much Debt?

Dec 17
Is CStone Pharmaceuticals (HKG:2616) Using Too Much Debt?

Analysts Expect Breakeven For CStone Pharmaceuticals (HKG:2616) Before Long

Apr 29
Analysts Expect Breakeven For CStone Pharmaceuticals (HKG:2616) Before Long

Earnings and Revenue Growth Forecasts

SEHK:2616 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20261,08669N/AN/A1
12/31/2025748-194N/AN/A1
12/31/2024569-26N/AN/A1
12/31/2023464-367-437-589N/A
9/30/2023472-559-487-548N/A
6/30/2023481-750-539-510N/A
3/31/2023481-827-626-561N/A
12/31/2022481-903-713-611N/A
9/30/2022454-1,205-966-841N/A
6/30/2022426-1,508-1,219-1,072N/A
3/31/2022335-1,714-1,426-1,278N/A
12/31/2021244-1,920-1,633-1,484N/A
9/30/2021681-1,622-1,241-1,103N/A
6/30/20211,118-1,324-848-722N/A
3/31/20211,079-1,272-714-615N/A
12/31/20201,039-1,221-580-508N/A
9/30/2020519-1,482-971-920N/A
6/30/2020-2-1,744-1,362-1,333N/A
3/31/2020-1-1,906-1,227-1,207N/A
12/31/2019N/A-2,069-1,091-1,081N/A
9/30/201911-1,688-907-898N/A
6/30/201912-1,246-706-699N/A
3/31/201912-858-752-745N/A
12/31/201813-470-799-791N/A
9/30/201813-336-693-679N/A
12/31/201710-107-253-240N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 2616 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.3%).

Earnings vs Market: 2616 is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: 2616 is expected to become profitable in the next 3 years.

Revenue vs Market: 2616's revenue (28.5% per year) is forecast to grow faster than the Hong Kong market (7.4% per year).

High Growth Revenue: 2616's revenue (28.5% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 2616's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y